A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recruiting · Phase 1 · NCT06465069
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
At a glance
- Research payments reported, 2025
- $2.7M
- U.S. investigators named
- 15
- Sites paid
- 13
- Planned or actual enrollment
- 460
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4052031 (drug), Pembrolizumab (drug)
- Dates
- Started 2024-07-01; completion 2027-05
- Results posted
- Not yet
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.7M in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Abhishek Tripathi, M.D. Medical Oncology · Duarte, CA
- Gerald S. Falchook, MD Medical Oncology · Denver, CO
- Alexander Philipovskiy, M.D., PH.D Medical Oncology · Sanford, FL
- Umang Swami, MD Hematology & Oncology · Iowa City, IA
- Peter Odonnell Internal Medicine · Chicago, IL
- Xin Gao, M.D. Hematology & Oncology · Boston, MA
- Nehal J. Lakhani, M.D. Hematology & Oncology · Grand Rapids, MI
- Melissa A. Reimers, MD Medical Oncology · Saint Louis, MO
- Matthew D. Galsky, MD Medical Oncology · New York, NY
- Gopakumar V. Iyer, M.D. Internal Medicine · New York, NY
- Alexander Z. Wei, MD Medical Oncology · New York, NY
- Benjamin Garmezy, MD Hematology & Oncology · Nashville, TN
- Amita Patnaik, M.D. Medical Oncology · San Antonio, TX
- Arlene O. Siefker-radtke, M.D. Medical Oncology · Houston, TX
- Justin A. Call, M.D. Medical Oncology · West Jordan, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering $638,846
- Sarah Cannon Research Institute LLC $356,983
- Dana Farber PArtners Cancer Care Inc $355,910
- South Texas Accelerated Research Therapeutics LLC $289,771
- Trustees of Columbia Univ in The City of Ny $243,833
- Start Ctr for Cancer Care $234,628
- Ut MD Anderson Cancer Center $156,703
- Mount Sinai School of Medicine $129,176
- Start Mountain Region LLC $77,610
- University of Chicago $73,531
- University of Utah Hospital and Clinics, UT $64,113
- City of Hope National Medical Ctr $52,082
- Washington University $8
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.